Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.

Inclusion Criteria: * Participant is aged 8 years to 17 years (inclusive) * Participant is at a healthy weight at the discretion of the Principal Investigator. * Parents or caregivers can give informed consent for participation in the trial with assent from individuals with autism. * Participants can comply with trial requirements. * According the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria the participant has a diagnosis of Level 2 or 3 Autism Spectrum Disorder (ASD) confirmed by Autism Diagnostic Observational Schedule (ADOS-2) criteria * All treatments including medications and therapies for ASD related symptoms must have been stable for 4 weeks before enrolment and for the duration of the trial wherever possible. * Participants must be able to swallow liquid. * Consent giver must be able to understand the requirements of the study. Exclusion Criteria: * Current diagnosis of bipolar disorder, psychosis, schizophrenia, schizoaffective disorder, or active major depression * Has a diagnosis other than ASD that dominates the clinical presentation (e.g., Attention Deficit Hyperactivity Disorder \[ADHD\]) * Has a degenerative condition * Changes in anticonvulsive therapy within the last 12 weeks * Taking omeprazole, lansoprazole, tolbutamide, warfarin, sirolimus, everolimus, temsirolimus, tacrolimus, clobazam, repaglinide, pioglitazone, rosiglitazone, montelukast, bupropion, or efavirenz * Currently using or has used recreational or med…